XHKG: 09939
Morningstar‘s Stock Analysis 09939
1-Star Price
INVESTOR
5-Star Price
INVESTOR
Economic Moat
INVESTOR
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile 09939
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-ß (GT90008), and AR-PROTAC Compound (GT20029). It operates in a single segment focusing on the research and development of medical products.
Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion.
Kintor Pharmaceutical Ltd Ordinary Shares
XHKG: 09939
| JW (Cayman) Therapeutics Co Ltd Ordinary Shares
XHKG: 02126
| Alphamab Oncology Ordinary Shares
XHKG: 09966
| 3SBio Inc Shs Unitary 144A/Reg S
XHKG: 01530
| |
Price
| 2.74 | 2.07 | 8.60 | 6.55 |
Currency
| HKD | HKD | HKD | HKD |
Change
| +$0.06 (2.24%) | +$0.02 (0.98%) | −$0.45 (4.97%) | −$0.15 (2.24%) |
Market Cap
| 1.23 Bil | 851.88 Mil | 8.30 Bil | 15.97 Bil |
Industry
| Biotechnology | Biotechnology | Biotechnology | Biotechnology |
Sector
|
Healthcare
|
Healthcare
|
Healthcare
|
Healthcare
|
* Trading data in this section is delayed by at least 15 minutes.
FAQs for Kintor Pharmaceutical Ltd Ordinary Shares Stock
No. 09939 does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
09939’s market cap is 1.23 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.
It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the
largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Learn more about market capitalization.
09939’s stock style is Small Value.
Style is an investment factor that has a meaningful impact on investment risk and returns.
Style is calculated by combining value and growth scores, which are first individually calculated.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
Learn more about style.
09939’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare 09939’s historical performance against its industry peers and the overall market.